Press releasePRNewswire
Immunic
IMUX · NASDAQ
$7.41+$0.42 (+6.01%)TodayMarket closed ·
Prev close $6.99
Latest news
- Press releasePRNewswire
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
- Press releasePRNewswire
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
- Press releasePRNewswire
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
- Press releasePRNewswire
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Press releasePRNewswire
Immunic Appoints Elena Ridloff to Board of Directors
- Press releasePRNewswire
Immunic to Participate in Investor Conferences in July
- Press releasePRNewswire
Immunic to Participate in Investor, Industry and Scientific Conferences in June
- Press releasePRNewswire
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
- Press releasePRNewswire
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
- Press releasePRNewswire
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
- News
Earnings Scheduled For May 13, 2026
- Press releasePRNewswire
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Press releasePRNewswire
Immunic to Participate in Investor and Medical Conferences in May
- Press releasePRNewswire
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
- Press releasePRNewswire
Immunic, Inc. Announces 1-for-10 Reverse Stock Split
- Press releasePRNewswire
Immunic, Inc. Announces 1-for-10 Reverse Stock Split
- NewsVandana Singh
Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says
- Press releasePRNewswire
Immunic to Participate in Scientific and Medical Conferences in April
- Press releasePRNewswire
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Press releasePRNewswire
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
- Press releasePRNewswire
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
- Press releasePRNewswire
Immunic to Participate in Investor Conferences in March
- Press releasePRNewswire
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
- Press releasePRNewswire
Immunic Announces Closing of Oversubscribed Private Placement Financing
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releasePRNewswire
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
- Press releasePRNewswire
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- NewsAvi Kapoor
This VSE Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.